A new treatment for cognitive impairment after traumatic brain injury.
Mitochondrial Uncoupling Prodrug as a Translational Therapy for TBI
['FUNDING_R01'] · UNIVERSITY OF KENTUCKY · NIH-10563194
This study is looking at a new treatment called MP201 that might help improve thinking and memory for people who have had a traumatic brain injury by boosting brain energy and reducing damage, and it will find out the best way to use this treatment for the best results.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF KENTUCKY (nih funded) |
| Locations | 1 site (LEXINGTON, UNITED STATES) |
| Trial ID | NIH-10563194 on ClinicalTrials.gov |
What this research studies
This research investigates a novel therapeutic approach for treating cognitive impairment resulting from traumatic brain injury (TBI). It focuses on a prodrug called MP201, which acts as a mitochondrial uncoupler to improve brain energy metabolism and reduce oxidative damage. The study aims to determine the optimal dosage and timing for administering MP201 to maximize its neuroprotective effects. By targeting mitochondrial dysfunction, the research seeks to enhance recovery and cognitive function in individuals affected by TBI.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals aged 21 and older who have experienced moderate to severe traumatic brain injury.
Not a fit: Patients with mild traumatic brain injury or those who do not have cognitive impairment may not receive benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to an effective treatment for improving recovery and cognitive function in patients with traumatic brain injury.
How similar studies have performed: Previous research has shown promising results with mitochondrial uncouplers in preclinical models, indicating potential for success in this approach.
Where this research is happening
LEXINGTON, UNITED STATES
- UNIVERSITY OF KENTUCKY — LEXINGTON, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: SULLIVAN, PATRICK G — UNIVERSITY OF KENTUCKY
- Study coordinator: SULLIVAN, PATRICK G
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.